CD274 and triple-negative breast carcinoma: This article has been cited for a total of 160 times, indicating the ability of the combination of atezolizumab and nab-paclitaxel to prolong progression-free survival in patients with advanced triple-negative breast cancer, particularly in the PD-L1 positive subgroup.